Who We Are

Ansun is leading the development of novel therapeutics to address unmet needs in viral disease and cancer by using its industry-leading expertise in sialic acid biology.

We are industry veterans with significant drug discovery, development and commercialization expertise. We share a vision of developing innovative products to save lives, especially for vulnerable and underserved patients.

Our Approach

We focus our drug development programs to directly target unmet medical needs.

Our lead product, DAS181, is a sialidase fusion protein that removes the sialic acid present on the host cell surface that certain viruses use to enter the cell; it was conceived and designed using knowledge of virus and host interaction and sialic acid biology. DAS181 is now undergoing a Phase 3 clinical trial for the treatment of human Parainfluenza Virus (“PIV”) in immunocompromised patients.

Leveraging Ansun’s deep knowledge of sialic acid biology, we develop state-of-the-art multi-modality therapeutics for the treatment of cancer. This has led to programs including oncolytic virus, tumor microenvironment (TME)-modulating bispecific antibodies, and tumor-targeting CAR-NK/γδ T cells.

Leadership Team

Dr. Nancy Chang

Dr. Nancy Chang

CEO and Chairperson of the Board

Nancy Chang, Ph.D., is CEO and Chairperson of the Board, and has served as a Director of Ansun since 2011. Nancy was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was acquired by Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of several companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., and Inspirna, Inc.  Nancy received her Doctorate in Biological Chemistry from Harvard University.

George Wang

Dr. George Wang

Chief Technology Officer

George Y. Wang, Sc.D., is the Chief Technical Officer at Ansun Biopharma.  Prior to joining Ansun in 2013, Dr. Wang oversaw all operations at A-Bio Pharma Pte Ltd. from 2004 until 2008. Prior to that, Dr. Wang served as Vice President of Process Development and Production at Tanox, Inc. from 1991 until 2002. Dr. Wang held various engineering positions at IDEC Pharmaceuticals, BP Amoco Corporation and MGI Pharmaceuticals, Inc. Dr. Wang received his Sc.D. in Biochemical Engineering from Massachusetts Institute of Technology.

Haiyan Jiang

Dr. Haiyan Jiang

Chief Scientific Officer

Haiyan Jiang, Ph.D., is CSO responsible for R&D in Oncology at Ansun.  Before joining Ansun in Oct 2020, she was a co-founder and Head of R&D in cell and gene therapy at Geneception in 2018 – 2020.  Prior to that, she was VP of Preclinical Sciences at Editas Medicine in 2016 – 2018, overseeing the translation of CRISPR therapeutics from research to IND.  From 2009 to 2015, she was Director/Sr Director at Biogen, where she led preclinical and clinical pharmacology for Alprolix and Eloctate.  She also initiated research of BIVV001 and led the collaborations on lentiviral gene therapy and genome editing.  Dr. Jiang’s earlier work included Jivi at Bayer in 2005 – 2009 and AAV gene therapy for Hemophilia at Avigen in 2001-2005.  She received her BS in Biochemistry at Fudan University in Shanghai, China, Ph.D. in oncology at University of Wisconsin-Madison, and postdoctoral training at University of California, San Francisco.

Shuanglian Li

Dr. Shuanglian Li

SVP Clinical Development

Shuanglian(Lian) Li, MD, Ph.D. is Senior Vice President, Clinical Development of Oncology at Ansun Biopharma, overseeing the company’s clinical development strategies and execution of clinical trials. Prior to joining Ansun, Dr. Li was the Head of Clinical Development at Geneception, where she was responsible for the clinical development strategy of hemophilia and metabolic disease gene therapy. Dr. Li assumed roles of increasing responsibility in Oncology Therapeutic Area Unit at Takeda and Ariad (acquired by Takeda in 2017) since 2015, where she led the development of the first in class EGFR exon 20 insertion inhibitor Mobocertinib from FIH to pivotal clinical trials supporting NDA. Dr. Li also holds various positions at Biogen, Pfizer and Sugen (acquired by Pfizer in 2003) and contributed to the approvals of Eloctate, Alprolix, and Sunitinib. Dr. Li received her M.D. from Beijing Medical University (Peking University since 2001) and her Ph.D. in Pharmaceutical Science from the University of California, San Francisco.

Dr. Jennifer Ho

Dr. Jennifer Ho

SVP Clinical Development and Operation

Dr. Ho, M.D., Ph.D. is  Senior Vice President, Clinical Development and Operation at Ansun Biopharma, overseeing DAS181 development strategies and clinical trials operation. Before joining Ansun in 2017, she was the co-founder and V.P. R&D and Clinical Trial Development at Steminent US, Inc., leading stem cell therapeutics programs. Before that, she was professor at Taipei Medical University and National Yang-Ming University and the Director of Medical Research and Clinical Trial Center at the Wan Fang Medical Center with 17 years clinical practice experiences. Dr. Ho is an inventor of 8 patents, an author of over 50 peer-reviewed publications, a recipient of the National Award from National Science Council (Ta-You Wu Memorial Award), and a four time recipient of the Best Clinical Research Award from Taipei Medical University.   Dr. Ho received her M.D. in 1998 from National Taiwan University and Ph.D. in Biopharmaceutical Science from the Institute of Biopharmaceutical Science, National Yang-Ming University.

Yongjian Wu

Dr. Yongjian Wu


Yongjian Wu, Ph.D., is the Vice President of CMC, leading the CMC development of Ansun’s immune-oncology programs comprising oncolytic virus, CAR-NK and bifunctional antibodies.  Dr. Wu  has over 20 years of experience in CMC development of biologics. Before joining Ansun in 2020, he was COO of MabPlex USA, a biologics CDMO. Before that, Dr. Wu held increasing responsibilities at Tanvex Biopharma as director, VP of R&D and CSO, advancing biosimilar programs from preclinical to BLA filing. Dr. Wu started his career in cell line development at Bayer and protein engineering at BioMarin. He spent six years in Analytical Development/QC at Genentech, first in bioassay development and then in protein analytical chemistry, contributing to a dozen INDs for MAbs and ADCs. Dr. Wu obtained his B.Sc. in biochemistry and Ph.D. in Immunology from University of Toronto. Dr. Wu’s postdoctoral research was done in the Department of Neurobiology at Stanford University.

Board of Directors

Nancy Chang, Ph.D

Nancy Chang, Ph.D.

Nancy Chang, Ph.D., is the Chairperson of the Board and has served as Director of Ansun since 2011.  She is a pioneer of the biopharmaceutical industry.  She was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of several companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., Inspirna . Nancy received her Doctorate in Biological Chemistry from Harvard University.

Allen Chao, Ph.D

Allen Chao, Ph.D.

Allen Chao, Ph.D. has served as a Director at Ansun since 2010.  Dr. Chao is a pioneer in the life sciences industry.  Since January 2008, Dr. Chao has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company.  Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Actavis plc), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue.

Michael Chang, PhD

Michael Chang, Ph.D.

Michael Chang, Ph.D. has served as Director of Ansun since 2014.  He is an accomplished biopharmaceutical scientist, executive and entrepreneur.  In 1994, Dr. Chang established Pharmanex, a health products company, which was acquired by NuSkin Enterprises, where he was appointed Chief Scientific Advisor. Prior to this, he founded Cinogen in 1993. Dr. Chang was formerly the Director of Medical Chemistry at Rhone-Poulenc Rorer and Deputy Director of Medicinal Chemistry at Merck, Sharpe & Dohme (US Merck). Dr. Chang received his Ph.D. in Organic Chemistry from Brandeis University, and conducted postdoctoral research at MIT. He received his BS in Chemistry from Fu Jen Catholic University in Taiwan. He holds 39 patents and has published more than 69 scientific papers in peer reviewed journals.

Dave Chen

Dave Chenn

Dave Chenn is the CEO and managing partner of Oceanpine Capital. Previously in 2005, Dave founded China Century Group and its several subsidiary companies, a large multinational company today, in the areas of technology, finance, energy, tourism and healthcare in major regions of China, Southeast Asia and United Sates. Prior to it, Dave had worked as a head of Oracle’s Great China Region Government Industry, director of product management/ marketing in Oracle’s Silicon Valley headquarters for five years, as well as at McKinsey and Emerson Electric in Chicago.

Dave also serves as both a council member and a global advisory board member of Booth Business School of University of Chicago; trustee of Culver Academies, Culver, Indiana; Asia Development Committee at Yale University; Vice Chairman of China Green Energy Fund; And trustee of Beijing Film Academy. With his philanthropy contribution of over $30 million and the great success of his entrepreneurship, he has been awarded as “Top Ten Reformer of China’s Growth in 2017”, “Innovation Leader of China’s Economy in 2016”, “China’s Top 20 Investor of Semiconductor in 2020”, “China’s Top 10 Investor of Biopharma in 2020”, “China’s Top 50 Investor in 2020”, etc. , among many others, and has been received by the top leaders of China several times.

Dave holds an MBA from University of Chicago Booth Business School, and a BS from Beijing Institute of Technology, China.

Yi Shi, Ph.D

Yi Shi, Ph.D.

Yi Shi, Ph.D., has served as Director of Ansun since April 2018.  He is the Founder and Managing Partner of Lilly Asia Ventures, a biomedical venture capital firm with focus on China and cross-border opportunities. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and an MBA degree , both from Duke University. He also has a  B.S. degree in Biology from the University of Science and Technology of China.

Michael Chao, MD

Michael Chao, M.D.

Michael Chao, M.D., is the Senior Managing Director of Relativity Healthcare Partners, LLC, a family office investment group dedicated to providing capital to companies developing promising technologies and/or offering novel services to address unmet needs. As a financier, Dr. Chao concentrates on investments that build preeminent healthcare companies. He has been involved with investments in various companies, including LensGen, Tanvex BioPharma, TenNor Therapeutics, EarLens, and Orphomed. He has served on the Board of Directors for MidLabs, BioAnalytix, and Owl Biomedical through successful exits.   Furthermore, Dr. Chao maintains a direct link to the healthcare community as a staff physician at the US Department of Veterans Affairs healthcare system, providing medical and surgical care for veterans and combat veterans from current and prior military conflicts.  Dr. Chao has served on Children’s Hospital of Orange County (CHOC) Foundation Board, where he chaired the Transformational Philanthropic Venture Funding Committee, which supports innovative ideas in pediatric health. Dr. Chao received his MD from University of California, Irvine and his BA in Biology from the University of Pennsylvania.

Aimin Wu

Aimin Wu

Mr. Wu has served as Director of Ansun since July of 2018.  Mr. Aimin Wu is the President and Managing Partner of Sinopharm Capital.  Prior to that, Mr. Wu served as the Chief Financial Officer of Sinopharm Group Co. Ltd. from July 2003 to December 2006. From 2007 to 2012, Mr. Wu served as the Vice President of Sinopharm Group Co. Ltd. In addition, Mr. Wu was a Director of Accord Pharma from January 2005 to April 2014, a Director of National Medicines from December 2005 to December 2008 and a supervisor of National Medicines from May 2009 to December 2011.  Mr. Wu has nearly 20 years of working experience in Chinese and international capital market operations, pharmaceutical industry strategic development, mergers and acquisitions, restructurings, business development and financial management.  Mr. Wu is a qualified accountant in the PRC.  He obtained an Executive MBA degree from Shanghai Jiao Tong University in December 2006, and a B.S.  degree in Engineering, Majoring in Economy, from Hunan University in July 1992.

Donald Payne, MBA, CPA

Donald Payne, MBA, CPA

Donald Payne, MBA, CPA has served as a Director at Ansun since April 2018. For the past 27 years Mr. Payne has held senior operating and financial positions in early-stage biopharmaceutical and medical device companies.  His operations experience includes authoring IND and IDE filings with the FDA, managing US and non-US clinical trials in oncology, establishing cGMP manufacturing operations, and managing preclinical efficacy and toxicology programs.  Mr. Payne has co-authored 9 scientific publications and is a co-inventor of two issued and one pending patent applications.  He has served as a director of public and private early-stage companies, including as the Chairman of the Audit Committee of a Nasdaq-listed company. As the chief financial officer of early-stage companies, he has participated in various public and private financings and listings on NYSE and Nasdaq.  He currently consults with biopharmaceutical and medical device companies focused in oncology.  Mr. Payne is a Summa Cum Laude graduate of Rice University with an MBA degree  in 1992 ( and a Summa Cum Laude graduate of Texas A&M University (1976) with a Bachelor in Business Administration.  Mr. Payne is a licensed CPA in Texas.

Karen Liu, Ph.D

Karen Liu, Ph.D.

Karen Liu, Ph.D., is a founding partner of 3E Bioventures Capital, a healthcare focused venture investment firm which invests in new drugs and innovative devices and diagnostics.  Prior to 3E, Dr. Karen Liu was a partner of Kaiwu Capital and Managing Director at CRCI Capital, always covering healthcare investing.  Dr. Liu received her Ph.D. in Immunology from Harvard University, Master of Medical Sciences degree from Harvard University, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB – Chungkong Graduate School of Business in China.